Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.76 USD
Change Today -1.12 / -1.58%
Volume 2.5M
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 11:15 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

P.O. Box 3190

Petach Tikva, 49131

Israel

Phone: 972 3 926 7267

Fax: 972 3 923 4050

ct to levodopa for the treatment of the signs and symptoms of Parkinson’s disease, the second most common neurodegenerative disorder. The company markets Azilect in the United States, Germany and certain other markets, while Lundbeck exclusively markets Azilect in the remaining European countries and certain other international markets. Azilect is protected in the United States by several patents that would expire between 2016 and 2027. The company holds European patents covering Azilect which are protected by Supplementary Protection Certificates in various European countries until 2019. Nuvigil (armodafinil), the R-isomer of modafinil, is indicated for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. Fentora/Effentora (fentanyl buccal tablet) is indicated for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer. Fentora/Effentora is protected by patents expiring between 2019 and 2028. Provigil (modafinil) is indicated for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder in the United States. Zecuity is a prescription transdermal system approved by the FDA for the acute treatment of migraine with or without aura in adults. The company’s CNS portfolio also includes: Actiq (fentanyl oral transmucosal lozenge) for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Amrix (cyclobenzaprine hydrochloride extended-release capsules) in the United States, for relief of muscle spasm in acute, painful, musculoskeletal conditions. Respiratory The company maintains a presence in the respiratory market, a core therapeutic area, by delivering a range of medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The company’s portfolio is centered on optimizing respiratory therapies for patients through novel delivery systems and therapies that address unmet needs. In 2013, the company acquired MicroDose Therapeutx and its proprietary inhalation technology ‘tidal inhaler’. The company is in the process of developing a range of inhaled medicines for use in the tidal inhaler. ProAir hydrofluoroalkane (HFA) inhalation aerosol with dose counter (albuterol sulfate) is indicated in patients four years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. QVAR (beclomethasone dipropionate HFA) is indicated as a maintenance treatment for asthma as a prophylactic therapy in patients five years of age or older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration. Duoresp Spiromax (budesonide/formoterol) is a combination of an inhaled corticosteroid and a long acting ß-agonist bronchodilator, and was approved for treatment of asthma and COPD in adults in the European Union (EU) by the European Medicines Agency (EMA) in a centralized procedure. In 2014, the company launched Duoresp Spiromax in various EU countries, including Germany, the U.K. and Spain. The company’s respiratory portfolio also includes Qnasl Nasal Aerosol (beclomethasone dipropionate HFA in a nasal actuator), for the treatment of seasonal and year-round nasal allergy symptoms in the United States, which was also approved by the FDA for a pediatric indication in December 2014. Oncology The company’s oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Treanda (bendamustine hydrochloride for injection) is approved in the United States for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The company markets the product only in the United States, and also holds rights to Treanda in certain other countries. Filgrastim and Granix (in the U.S.) and Lonquex (lipegfilgrastim) ar

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $69.76 USD -1.12

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.62 USD -0.44
AbbVie Inc $70.26 USD -0.51
AstraZeneca PLC 4,326 GBp +135.00
Eli Lilly & Co $84.02 USD -1.07
Medtronic PLC $77.72 USD -0.16
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 22.3x
Price/Sales 3.0x
Price/Book 2.7x
Price/Cash Flow 24.9x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.